Cannabidiol-based lipid nanocarriers with analgesic activity
Abstract Pain remains a major clinical challenge due to its complex and multifactorial nature. The available treatments, such as conventional analgesics and opioids, often fail to provide adequate relief and are associated with limitations, including cardiovascular toxicity and short duration of action. This scenario reinforces the urgent need for safer and more effective therapeutic approaches. Cannabidiol (CBD) has emerged as a promising alternative in the pain management. Nanoencapsulation based on nanostructured lipid carriers (NLC) offers a potential strategy to overcome
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in
